{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-113659","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.180568+00:00","generated_at":"2026-05-30T06:19:57.156857+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves Emrosi for rosacea; Q3 prelim revenue $14.6M, net loss $2.4M; FY guidance unchanged","bullets":["FDA approved Emrosi (minocycline HCl ER 40 mg) for inflammatory lesions of rosacea in adults; initial supply expected late Q1 or early Q2 2025.","Q3 2024 prelim net product revenue $14.6M (vs $15.3M YoY); net loss $2.4M (vs $16.8M net income Q3 2023 which had $19.3M license payment).","Nine-month 2024 net product revenue $42.5M (vs $44.4M); net loss $16.2M (vs $1.7M); R&D $9.6M includes $4.1M FDA fee and $3.0M milestone to DRL.","FY 2024 guidance unchanged: net revenue $55-60M, SG&A $39-42M, R&D $9-10M.","Approval triggered $15M milestone to Dr. Reddy's; mandatory $5M draw under SWK Credit; expects $4.4M recovery from 2021 cyber incident in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-113659","json":"https://secwatch.observer/filing/0001104659-24-113659.json","markdown":"https://secwatch.observer/filing/0001104659-24-113659.md","text":"https://secwatch.observer/filing/0001104659-24-113659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924113659/0001104659-24-113659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465924113659/tm2427383d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:19:57.156857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}